CTX112 (Zugocabtagene geleucel) (CRSP-AID-502)
- Indication
- Adult Participants With Refractory Neurologic Autoimmune Disease Progressive Multiple Sclerosis (PMS) Neuromyelitis Optica Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Autoimmune Encephalitis Stiff-Person Syndrome
- Stage
- phase1
- Event
- Conference Presentation
- Details
Oct. 2, 2026: CRISPR Therapeutics (NASDAQ: CRSP) announced that Phase 1 clinical data for zugocabtagene geleucel (zugo-cel), its investigational CRISPR/Cas9 gene-edited allogeneic anti-CD19 CAR T-cell therapy, will be presented at ACR Convergence 2026 in refractory systemic sclerosis.
The data will be presented in a poster titled “Safety and Efficacy of Anti-CD19 Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy Zugocabtagene Geleucel (zugo-cel) in Patients with Refractory Systemic Sclerosis” (Abstract 0225) during Poster Session A on November 8, 2026, at 10:30 a.m. ET.
No efficacy or safety results were disclosed in the press release itself. The company said zugo-cel is being evaluated in Phase 1 trials across autoimmune diseases, including rheumatologic, hematologic, and neurologic indications. A copy of the presentation will be posted on the company’s website after the session concludes.
- Source
- View catalyst source ↗